ANZCTR search results

In this study, we will collect tonsil tissue that would normally be thrown away during tonsil removal surgery. We will use this tissue in the lab to study how certain pathogens, including strep A and Epstein-Barr virus, affect people differently based on their tonsil cells and immune structures. We hyopthesise that children may have different levels of vulnerability to these pathogens depending on the unique features of their tonsil cells and immune tissue.

The purpose of this study is to investigate whether the use of earplugs at night will improve our patients sleep and reduce the numbers of patients who develop delirium (a sudden change in your health condition that may include confused thinking or unsettled behaviour) while in ICU.

It is hypothesed that pulsed-field ablation will result in better acute procedural outcomes than radiofrequency ablation. This is a multi-centre, randomised control trial of two ablations systems for atrial fibrillation. Participants referred for repeat AF ablation will be screened and randomised to repeat atrial fibrillation with pulsed-field ablation or radiofrequency ablation. The primary outcome is acute posterior wall isolation. The secondary outcomes include acute pulmonary vein isolation, AF recurrence as assessed by 3 and 12-month Holter monitor, left atrial (LA) physiology and procedural metrics.

Oxidative stress plays a central role in the development of Type 2 Diabetes. However, studies investigating the effect of antioxidant supplements on glycaemic control in people with type 2 diabetes have been equivocal. We hypothesise that adopting a targeted approach to antioxidant supplementation will be effective in improving glycaemic control in people with type 2 diabetes. The aim of this study is to determine the effect of targeted and untargeted antioxidant treatments on glycaemic control and exercise capacity in people with type 2 diabetes.

This study will test whether cannabidiol (CBD) alongside antipsychotic medication can reduce psychotic symptom severity in young people with first episode psychosis (FEP) for whom antipsychotic treatment is not showing efficacy. CBD has been shown to reduce psychotic symptoms in adults with schizophrenia. It is non-intoxicating and non-addictive with a high margin of safety, and its side-effect profile is far superior to that of antipsychotic medications. This will be the first study to test its efficacy in FEP. Consenting 15-25 year-olds with FEP who have not responded to at least one adequate trial of antipsychotic medication and are within 2 weeks of commencing a new antipsychotic medication will be randomised to receive either 1000mg of CBD or placebo per day for 12 weeks in addition to their current antipsychotic medication and clinical care.

This study aims to test a wearable auditory feedback system designed to help people with neurological conditions, such as stroke or Parkinson's disease, improve their walking. The device provides real-time sound cues during walking exercises, which guide participants in adjusting their steps and movement patterns. We hypothesise that using this auditory feedback system will improve key walking measures, such as stride length, walking speed, and balance, when compared to walking without feedback. The study will evaluate how well this system helps participants walk more steadily and confidently. Participants will take part in walking exercises on a treadmill, both with and without the feedback device, and we will measure improvements in their walking performance across different conditions. This study aims to provide insights into whether this system can be used as an effective tool in rehabilitation programs for those with walking difficulties due to neurological conditions.

Despite the technological innovation and potential for improved care, the use of digital drainage systems has not been well evaluated for trauma care. Decreasing the length of time that patients have an invasive intrathoracic device is expected to impact length of stay (LOS) in hospital, intensive care, and risk of adverse outcomes. This study aims to investigate the efficacy of digital thoracostomy drain in the setting of major thoracic trauma and we hypothesize that it could reduce the length of inter-costal catheterisation (ICC) time compared to the analogue counterpart.

Young Australians have the highest incidence of anterior cruciate ligament (ACL) injury, with females showing the steepest rise due to greater participation trends in high-risk sporting activities.. Unfortunately, many of these people will experience ACL graft failure, secondary knee injuries, sport/activity limitations, persistent pain, and impaired quality of life despite ACL reconstructive surgery (ACLR). Athletic footwear with appropriate design features (e.g., full-length, medial wedged insole) may reduce harmful loads on the ACL and knee cartilage leading to better outcomes following ACLR.

Pilots Part A and B of the ERASE study aim to develop a method for using Stereotactic Ablative Radiation Therapy (SABR) that accounts for both the anatomy (the shape and position of the cancer) and the biological response to immunotherapy. These pilot studies will establish and test the planning and treatment workflow for delivering response- and anatomical-adapted SABR. Successful treatment of participants in these pilot studies will help to demonstrate that this treatment approach can be delivered. Who is it for? You may be eligible for this study if you are an adult receiving first line programmed death (PD)-1 backbone immunotherapy for metastatic melanoma and showing an incomplete metabolic response to this immunotherapy 3 months after commencement. You will have a maximum of 5 metastases which are not showing complete metabolic response to immunotherapy and are radiologically defined targets which are suitable for treatment with SABR. Study details Participants will either receive standard of care (immunotherapy with immune checkpoint inhibitors) without SABR or one to three rounds of SABR to up to 5 new or SABR-naïve lesions. Your response to immunotherapy at 3 months after commencement will help to determine whether you will receive SABR. If you do not receive SABR at 3 months you may still receive SABR at 6 and/or 9 months after commencement of immunotherapy based on your responses at those times. Lesions will only be treated once with SABR. Data on participant response to treatment and any adverse events will be collected. It is hoped that findings from these pilot studies can support the use of response- and anatomical-adapted SABR in the treatment of metastatic melanoma and thereby minimise the radiation dose delivered to the important nearby organs, whilst potentially increasing the doses of radiation delivered to metastatic lesions. This personalised approach could avoid over-treating patients who respond well to immunotherapy and allow for higher doses for patients who don't respond as well.

The ERASE study aims to develop a method for using Stereotactic Ablative Radiation Therapy (SABR) that accounts for both the anatomy (the shape and position of the cancer) and the biological response to immunotherapy and demonstrate that this approach is effective in treating metastatic melanoma. Who is it for? You may be eligible for this study if you are an adult receiving first line programmed death (PD)-1 backbone immunotherapy for metastatic melanoma and showing an incomplete metabolic response to this immunotherapy 3 months after commencement. You will have a maximum of 5 metastases which are not showing complete metabolic response to immunotherapy and are radiologically defined targets which are suitable for treatment with SABR. Study details Participants will either receive standard of care (immunotherapy with immune checkpoint inhibitors) without SABR or one to three rounds of SABR to up to 5 new or SABR-naïve lesions. Your response to immunotherapy at 3 months after commencement will help to determine whether you will receive SABR. If you do not receive SABR at 3 months you may still receive SABR at 6 and/or 9 months after commencement of immunotherapy based on your responses at those times. Lesions will only be treated once with SABR. Data on participant response to treatment and any adverse events will be collected. It is hoped that findings from this study can support the use of response- and anatomical-adapted SABR in the treatment of metastatic melanoma and thereby minimise the radiation dose delivered to the important nearby organs, whilst potentially increasing the doses of radiation delivered to metastatic lesions. This personalised approach could avoid over-treating patients who respond well to immunotherapy and allow for higher doses for patients who don't respond as well.